Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain." A pharmacist ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...

Say, perhaps, a daily glass to unwind with that's just for you. Enter: the wine advent calendar. Like the candy-filled advent calendars you grew up with, but with a very different sort of treat ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...

More than three-quarters (77%) of health care providers surveyed stated that treating moderate-to-severe acute pain with ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Snap SNAP shares have declined 35.3% year to date (YTD), underperforming the broader Zacks Computer and Technology sector’s ...